title: Using Health Care Claims Data to Assess the Prevalence of Hodgkin Lymphoma and Relapsed or Refractory Hodgkin Lymphoma in the United States.
abstract: Although most patients with Hodgkin lymphoma (HL) respond to primary therapy, some patients experience relapses or are refractory to treatment (RR-HL). The objectives of this study were to investigate the prevalence of HL and RR-HL in the United States by using a large health care claims database.
  
  
  
  Patients with ≥1 diagnosis for HL between January 1, 2013, and September 30, 2014 (prevalence assessment period), in the MarketScan Commercial and Medicare databases were identified. RR-HL patients were identified as any HL patient with any record for either an autologous stem cell transplantation (ASCT) or brentuximab vedotin (BV) treatment between January 1, 2010, and September 30, 2014 (entire study period). Prevalence rates of HL and RR-HL were calculated as the number of patients with HL or RR-HL divided by the total number of persons with insurance enrollment during the prevalence assessment period (January 1, 2013-September 30, 2014) in the MarketScan databases. Age- and sex-specific prevalence rates for HL and RR-HL were estimated. The estimated prevalence rates based on the claims database analysis were applied to the US national population estimates from the US Census Bureau to project the national prevalence of HL and RR-HL in the United States.
  
  
  
  Of persons with any insurance enrollment in the MarketScan databases during the prevalence assessment period (N = 58,968,235), 24,812 (0.04%) were identified as having HL (mean age, 48.6 years) between January 1, 2013, and September 30, 2014. Of this HL population, 712 (2.87%) were identified as RR-HL patients, with 432 (1.74%) having received ASCT, 199 (0.80%) having received BV, and 81 (0.33%) having received both ASCT and BV treatments during the study period. According to the national projection according to the US Census population estimate, the overall number of persons with HL in the United States was estimated at 149,615 (469.2 per 1 million) in 2014, with 2.72% (N = 4077; 12.8 per 1 million) having RR-HL.
  
  
  
  Among patients in the United States with HL, the proportion of RR-HL patients during the study period was estimated at <3% of the HL population.
authors.affiliation: Novosys Health, Green Brook, New Jersey. Electronic address: jay.lin@novosyshealth.com.
authors.forename: Jay
authors.initials: J
authors.lastname: Lin
authors.affiliation: Bristol-Myers Squibb, Plainsboro, New Jersey.
authors.forename: Lisa R
authors.initials: LR
authors.lastname: Siegartel
authors.affiliation: Novosys Health, Green Brook, New Jersey.
authors.forename: Melissa
authors.initials: M
authors.lastname: Lingohr-Smith
authors.affiliation: Novosys Health, Green Brook, New Jersey.
authors.forename: Brandy
authors.initials: B
authors.lastname: Menges
authors.affiliation: Bristol-Myers Squibb, Plainsboro, New Jersey.
authors.forename: Dinara
authors.initials: D
authors.lastname: Makenbaeva
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000079963:Brentuximab Vedotin; D002648:Child; D002675:Child, Preschool; D005260:Female; D006689:Hodgkin Disease / Q000453:epidemiology* / Q000628:therapy; D006801:Humans; D018796:Immunoconjugates / Q000008:administration & dosage*; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D006278:Medicare; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D015995:Prevalence; D033581:Stem Cell Transplantation / Q000379:methods*; D014481:United States; D055815:Young Adult
chemical_list: D018796:Immunoconjugates; D000079963:Brentuximab Vedotin
keywords: Hodgkin lymphoma; prevalence; relapsed or refractory Hodgkin lymphoma